Leadership and Administration Core

领导和管理核心的目标是确保POCRC的转化目标 并确保资源得到有效利用。领导核心负责持续评估 所有项目的科学和转化进展。如果进展不够，执行委员会 由主要研究者Nicole Urban博士和共同主要研究者玛丽（诺拉）Disis博士组成， 查尔斯·德雷舍尔、贝丝·卡兰、史蒂夫·柯林斯和马丁（麦克）·奇弗将采取必要的行动。的 执行委员会还负责确保核心资源满足项目需求， 冗余或冲突，提供科学的领导，促进跨SPORE沟通，协调 协作，整合POCRC和CCSG活动，并分配SPORE资源。 领导核心将负责协调SPORE活动并确保沟通 在核心、项目和委员会之间。领导核心内的委员会将包括 患者倡导小组成员的代表，以确保POCRC始终 致力于实现其转化目标并满足患者的需求。领导核心 将为SPORE的翻译活动提供全面指导， 跨学科合作。它将促进、监督和评估核心之间的积极互动 和项目。通过咨询委员会，领导核心将提供 以下职能：1）全面管理和协调SPORE; 2）满足科学咨询 个人研究项目的需求; 3）监督，计划和评估SPORE的业绩，包括国际合作; SPORE活动; 4）促进，监督和评估核心和项目的互动; 5）鼓励，选择， 并指导发展项目; 6）提供指导和职业发展; 7）管理，分配， 适当时重新分配SPORE资金和其他资源; 8）监督IRB活动; 9）确保 科学目标最终可以转化为病人护理; 10）发起新的活动，以应对 重要的转化研究机会。 为了满足项目和核心的需求，卵巢癌，转化研究，早期 检测/筛查、流行病学、基因组学、免疫学、统计方法、信息学和病理学 已被确定并招募为领导核心。具有相关专业知识的高级领导人 将在实质性委员会中相互交流，并向太平洋区域合作中心提供指导 调查人员是自己领域的专家，但对其他关键学科不太熟悉， 卵巢癌转化研究的职业发展和POCR的总体成功（Z;. 相关性（参见说明）： 这个卵巢孢子的目标是证明更好的策略：1）筛查高危妇女， 新的血清标志物和最先进的成像，而不需要另一个大的试验，通过整合我们的 I期试验结果和正在进行的III期疗效试验的报告; 2）选择女性进行新辅助治疗 通过测试她们的血液来获得可切除性特征的治疗;以及3）使妇女对自己的 防止肿瘤复发。如果这些努力中的一项或多项取得成功， 卵巢癌

The goal of the Leadership and Administration Core is to ensure that translational goals of the POCRC are met and that resources are used effectively. The Leadership Core is responsible for ongoing evaluation of scientific and translational progress of all projects. If progress is not sufficient, the Executive Committee comprised of Dr. Nicole Urban, Principal Investigator, and co-principal investigators, Drs. Mary (Nora) Disis, Charles Drescher, Beth Karlan, Steve Collins, and Martin (Mac) Cheever, will take necessary action. The Executive Committee is also responsible for ensuring that cores meet the needs of projects without redundancy or confiict, providing scientific leadership, facilitafing Inter-SPORE communication, coordinafing collaborations, integrating POCRC and CCSG activities, and allocating SPORE resources. The,Leadership Core will be responsible for coordinating SPORE activities and assuring communication between the cores, projects and committees. Committees within the Leadership Core will include representation from members ofthe Patient Advocate Group to make certain that the POCRC constanfiy works towards achieving its translational goals and meeting the needs ofthe patient. The Leadership Core will provide overall guidance for the translational activities ofthe SPORE, building on established interdisciplinary collaborations. It will promote, oversee, and evaluate active interaction between the cores and the projects. Through the advisory boards and committees, the Leadership Core will provide the following functions: 1) overall management and coordination ofthe SPORE; 2) meet the scientific advisory needs of the individual research projects; 3) oversee, plan, and evaluate SPORE acfivifies including inter¿ SPORE activities; 4) promote, oversee, and evaluate interaction of cores and projects; 5) encourage, select, and guide developmental projects; 6) provide mentoring and career development; 7) manage, distribute, and re-allocate SPORE funds and other resources as appropriate; 8) oversee IRB activity; 9) ensure that scientific objectives can ultimately be translated to patient care; 10) initiate new activities in response to important translational research opportunities. To address the needs of the projects and the cores, experts in ovarian cancer, translational research, early detection/screening, epidemiology, genomics, immunology, statistical methods, informatics, and pathology have been identified and recruited to serve in the Leadership Core. Senior leaders with relevant expertise will interact with each other on substantive committees as well as provide mentorship to POCRC investigators who are experts in their own fields but less acquainted with other disciplines that are critical to career development in ovarian cancer translational research and the overall success ofthe POCR(Z;. RELEVANCE (See instructions): The goal of this ovarian SPORE is to demonstrate better strategies for 1) screening high-risk women using novel serum markers and state-of-the-art imaging without the need for another large trial, by integrating our Phase I trial results with reports from ongoing Phase III efficacy trials; 2) selecting women for neoadjuvant therapy by testing their blood for a resectability signature; and 3) immunizing women against their own tumors to prevent recurrence. Success in one or more of these efforts will significantly reduce the burden of ovarian cancer.